Abstract | BACKGROUND: BRAF gene mutation causes melanoma patients to develop drug resistance after 8-9 months BRAF inhibitors treatment. Therefore, overcoming BRAF inhibitor resistance has important implications for improving patient survival. Sorafenib directly inhibits tumor cell proliferation by blocking the RAF/ MEK/ERK-mediated cell signaling pathway. It remains unknown that whether the combination of sorafenib with vemurafenib could sensitize melanoma cells to vemurafenib, and the underlying mechanism needs to be clarified. METHODS: RESULTS: CONCLUSIONS:
|
Authors | Fengjie Tang, Shiyan Li, Daisong Liu, Jian Chen, Chaofei Han |
Journal | Translational cancer research
(Transl Cancer Res)
Vol. 9
Issue 3
Pg. 1584-1593
(Mar 2020)
ISSN: 2219-6803 [Electronic] China |
PMID | 35117506
(Publication Type: Journal Article)
|
Copyright | 2020 Translational Cancer Research. All rights reserved. |